croi-2013-pocket-program

Tuesday
March 5 Oral Sessions
Session 26 CROI 2013
11:00 102 The E138A Mutation in HIV-1 Reverse
Transcriptase Is More Common in Subtype C
than B and Decreases Susceptibility to NNRTI
Nicolas Sluis-Cremer* 1 , K Huber 1 , C Brumme 2 , C Wallis 3 ,
J Mellors 1 , and R Harrigan 2
1 Univ of Pittsburgh Sch of Med, PA, US;; 2 BC Ctr for Excellence in
HIV/AIDS, Vancouver, Canada;; and 3 Lancet, Johannesburg, South
Africa
11:15 103 Non-Catalytic Site Integrase Inhibitors Target
the Integrase Domain during Virus Production
and Induce a Reverse Transcription Block
Stephen Yant*, L Tsai, C O’Sullivan, T Cihlar, and M Balakrishnan
Gilead Sci, Foster City, CA, US
11:30 104 Viral Particles Produced in Presence of LEDGIN
Are Impaired for Infectivity
B Desimmie 1 , Frauke Christ* 1 , W Thys 1 , J Demeulemeester 1 ,
D Borrenberghs 1 , R Schrijvers 1 , J Hofkens 1 , N Bannert 2 , and Z Debyser 1
1 Katholieke Univ Leuven, Belgium and 2 Robert Koch Inst, Berlin,
Germany
11:45 105 Potent Antiviral Activity of 2nd Generation
Maturation Inhibitors Against Bevirimat-resistant
Polymorphic HIV-1 Isolates
E Urano 1 , S Ablan 1 , D Martin 2 , T Nitz 2 , E Freed 1 , and Carl Wild* 2
1 NCI-Frederick, MD, US and 2 DFH Pharma, Inc, Gaithersburg, MD, US
12:00 106LB Week-24 Primary Analysis of Cenicriviroc
vs Efavirenz, in Combination with
Emtricitabine/Tenofovir, in Treatment-naïve
HIV-1 + Adults with CCR5-tropic Virus
Joseph Gathe* 1 , J Cade 2 , E DeJesus 3 , J Feinberg 4 , J Lalezari 5 ,
J Morales-Ramirez 6 , A Scarsella 7 , M Saag 8 , M Thompson 9 ,
and E Lefebvre 10
1 Therapeutic Concepts, Houston, TX, US;; 2 Nevada AIDS Res Ed
Society, Las Vegas, US;; 3 Orlando Immunology Ctr, FL, US;; 4 Univ
of Cincinnati, OH, US;; 5 Quest Clin Res, San Francisco, CA, US;;
6 Clin Res PR, Inc, San Juan, Puerto Rico;; 7 Pacific Oaks Med Group,
Beverly Hills, CA, US;; 8 Univ of Alabama at Birmingham, US;; 9 AIDS
Res Consortium of Atlanta, GA, US;; and 10 Tobira Therapeutics, Inc,
San Francisco, CA, US
b Tuesday, 1:30-2:30 pm; B402
Session 27–Themed Discussion
(see Session 95 on Monday for corresponding Poster Abstracts)
Mining Sequence Data to Understand
Transmission and Disease
Discussants:
Chanson Brumme, BC Ctr for Excellence in HIV/AIDS, Vancouver,
Canada
Jacques Fellay, Fed Inst of Tech, Lausanne, Switzerland
488 The Global Transmission Network of HIV-1
Joel Wertheim* 1 , A Leigh Brown 2 , L Hepler 1 , S Mehta 1 , D Richman 1,3 ,
D Smith 1,3 , and S Kosakovsky Pond 1
1 Univ of California, San Diego, US;; 2 Univ of Edinburgh, UK;; and 3 VA San
Diego Hlthcare System, CA, US
489 Frequent HIV Introductions into Communities
Sustain Local Epidemics in Rural Rakai, Uganda
Mary Grabowski* 1 , J Lessler 1 , A Redd 2 , O Laeyendecker 2,3 ,
J Kagaayi 4 , T Lutalo 4 , M Wawer 1,4 , D Serwadda 4,5 , T Quinn 2,3 , R Gray 1,4 ,
and Rakai Hlth Sci Prgm
1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;;
2 Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US;; 3 Johns
Hopkins Univ Sch of Med, Baltimore, MD, US;; 4 Rakai Hlth Sci Prgm,
Entebbe, Uganda;; and 5 Makerere Univ Sch of Med, Kampala, Uganda
490 Dynamics of Non-B HIV Transmission in the UK
Manon Ragonnet-Cronin* 1 , S Lycett 1 , E Hodcroft 1 , S Hue 2 ,
E Fearnhill 3 , D Dunn 3 , V Delpech 4 , A Leigh Brown 1 , and UK Collaborative
Group on HIV Drug Resistance
1 Univ of Edinburgh, UK;; 2 Univ Coll London, UK;; 3 MRC Clin Trials Unit,
London, UK;; and 4 Hlth Protection Agency, London, UK
491 Defining HLA Genotypes from Bulk HIV Sequences
A Kreimer 1 , M Shaefer 2 , N Pfeifer 1 , V Tan 1 , P Goulder 3 , M John 4 ,
Z Brumme 5 , E Hunter 2 , D Heckerman 1 , Jonathan Carlson* 1 ,
and Intl and Southern Africa HIV Assn Collaboratives
1 Microsoft Res, Los Angeles, CA, US;; 2 Emory Univ, Atlanta, GA, US;;
3 Univ of Oxford, UK;; 4 Murdoch Univ, Australia;; and 5 Simon Fraser Univ,
Burnaby, Canada
492 Whole Genome Sequencing of HIV + African
Americans with Rapid Disease Progression or Longterm
Non-progression
Amy Weintrob* 1,2 , K Pelak 3 , R Thomas 2 , P Ehrenberg 2 , P Shea 3 ,
J Okulicz 1 , A Ganesan 1 , B Agan 1 , N Michael 2 , and D Goldstein 3
1 Uniformed Svcs Univ Infectious Disease Clin Res Prgm, Bethesda, MD,
US;; 2 Military HIV Res Prgm, Bethesda, MD, US;; and 3 Duke Univ Ctr for
Human Genome Variation, Durham, NC, US
12 � 20th Conference on Retroviruses and Opportunistic Infections
493 Exome Sequencing of Elite and Rapid HIV
Progressors: Results from the Exploratory Pilot
of the UK HIV Genomics Consortium
Deepti Gurdasani* 1,2 , C Scott 1 , E Young 1,2 , K Porter 3 , P Kellam 1,4 ,
M Sandhu 1,2 , and UK HIV Genomics Consortium
1 Wellcome Trust Sanger Inst, Cambridge, UK;; 2 Univ of Cambridge, UK;;
3 MRC Clin Trials Unit, London, UK;; and 4 Univ Coll London, UK
b Tuesday, 1:30-2:30 pm; B406
Session 28–Themed Discussion
(see Session 59 on Monday for corresponding Poster Abstracts)
Restriction Factors: Old and New
Discussants:
Nathaniel Landau, New York Univ Sch of Med, NY, US
Stuart Neil, King’s Coll London Sch of Med, Guy’s Hosp, UK
222 Evolutionarily Conserved Requirement of CBF-� for
the Assembly of HIV/SIV Vif Cul5 Cullin-Ring Ligase
Sean Evans* 1 , X Han 1,2 , X Zhou 1,2 , J Du 2 , W Zhang 2 , G Wang 2 ,
and X-F Yu 1,2
1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and
2 First Hosp of Jilin Univ, China
223 Sooty Mangabey SIV, the Ancestor of HIV-2,
Efficiently Counteracts Human APOBEC3G
Michael Letko* 1 , M Ooms1 , G Silvestri2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US and Emory Univ Sch of Med,
Atlanta, GA, US
224 Exploring the Relationship between P-body
Localization and Virion Incorporation of Human
Antiviral Proteins APOBEC3G and Mov10
Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak
HIV Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick, MD,
US
225 HIV-1 Vpr Targets Restriction Factor CTIP2
to Proteasomal Degradation
Sultan Ali* 1 , C Schwartz1,2 , and O Rohr1,2 1 2 Univ of Strasbourg, France and IUT of Schiltigheim, Strasbourg, France
226 Small Molecule Compounds Inhibit Vpu-mediated
Down-regulation BST-2
Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen
Inst of Med Biotech, Chinese Academy of Med Sci, Beijing
227 Novel Regulation of SIV Vpx-mediated SAMHD1
Degradation
Wei Wei* 1 , H Guo 1 , X Han 1 , X Liu 1 , S Evans 2 , X Zhou 2 , W Zhang 1 , and X-F Yu 2
1 First Hosp of Jilin Univ, Inst of Virology and AIDS Res, China and 2 Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US
b Tuesday, 1:30-2:30 pm; B308
Session 29–Themed Discussion
(see Session 189 on Wednesday for corresponding Poster Abstracts)
MSM in the Developing World
Discussants:
Chris Beyrer, John Hopkins Univ Bloomberg Sch of Publ Hlth,
Baltimore, MD, US
Harold Jaffe, CDC, Atlanta, GA, US
1021 HIV Prevalence and Associated Risk Factors among
MSM: A Respondent-driven Sampling Survey,
Abidjan, Cote d’Ivoire
Avi Hakim* 1 , J Aho 2 , G Semde 3 , M Diarrassouba 4 , K Ehoussou 4 ,
B Vuylsteke 2 , C Murrill 1 , M Thiam 5 , T Wingate 4 , and SHARM Study Group
1 CDC, Atlanta, GA, US;; 2 Inst of Tropical Med, Antwerp, Belgium;; 3 Family
Hlth Intl 360, Abidjan, Cote d’Ivoire;; 4 CDC, Abidjan, Cote d’Ivoire;; and
5 Ministry of Hlth and Publ Hygiene, Abidjan, Cote d’Ivoire
1022 HIV Prevalence and Correlates of Infection among
MSM: 4 Areas in Ghana, the Ghana Men’s Health
Study, 2010-2011
John Aberle-Grasse* 1 , W McFarland 2,3 , A El-Adas 4 , S Quaye 1 ,
K Atuahene 4 , W Ampofo 5 , R Adanu 6 , S Chaturvedi 2 , R Fisher 2 ,
and E Harrison 5
1 CDC, Atlanta, GA, US;; 2 Univ of California, San Francisco, US;; 3 San
Francisco Dept of Publ Hlth, CA, US;; 4 Ghana AIDS Commission, Accra;;
5 Univ of Ghana, Noguchi Memorial Inst for Med Res, Legon;; and 6 Univ of
Ghana, Sch of Publ Hlth, Legon